https://www.pinneyassociates.com/ 2024-07-31T19:21:17+00:00 https://www.pinneyassociates.com/events-ideas/ 2026-03-09T15:38:45+00:00 https://www.pinneyassociates.com/tobacco-harm-minimization/ 2025-05-14T21:13:48+00:00 https://www.pinneyassociates.com/dietary-ingredients-and-supplements/ 2024-08-01T18:58:08+00:00 https://www.pinneyassociates.com/prescription-medicines/ 2023-10-05T17:25:56+00:00 https://www.pinneyassociates.com/about-pinney-associates/ 2025-08-05T18:51:06+00:00 https://www.pinneyassociates.com/contact/ 2025-04-22T14:22:48+00:00 https://www.pinneyassociates.com/our-team/ 2023-10-13T19:12:10+00:00 https://www.pinneyassociates.com/otc-products/ 2025-02-11T14:50:16+00:00 https://www.pinneyassociates.com/the-abuse-potential-of-7-hydroxymitragynine-7-oh-according-to-the-8-factors-of-the-controlled-substances-act-2/ 2026-03-09T15:38:45+00:00 https://www.pinneyassociates.com/indigenous-knowledge-systems-psychedelic-science-towards-ethical-and-reciprocal-collaboration/ 2026-02-05T17:50:30+00:00 https://www.pinneyassociates.com/abuse-potential-assessment-of-novel-central-nervous-system-active-and-psychedelic-substances-for-controlled-substances-act-scheduling-recommendations/ 2025-12-18T16:10:01+00:00 https://www.pinneyassociates.com/comment-to-fda-on-tobacco-product-standard-for-nicotine-yield-of-cigarettes-and-certain-other-combusted-tobacco-products/ 2025-09-18T14:43:39+00:00 https://www.pinneyassociates.com/team/lynne-dawkins/ 2025-08-19T13:35:24+00:00 https://www.pinneyassociates.com/kratom-use-in-the-context-of-addiction-treatment/ 2025-06-03T17:51:47+00:00 https://www.pinneyassociates.com/national-geographic-recognizes-otc-oral-contraceptive-opill-as-a-key-medical-breakthrough-in-2024/ 2025-01-23T20:06:45+00:00 https://www.pinneyassociates.com/adherence-among-a-cohort-taking-progestin-only-pills-prescribed-by-a-healthcare-provider-results-of-the-benchmark-study-2/ 2025-01-23T18:56:19+00:00 https://www.pinneyassociates.com/kratom-safety-and-toxicology-in-the-public-health-context-research-needs-to-better-inform-regulation/ 2024-07-26T17:24:56+00:00 https://www.pinneyassociates.com/comment-on-nda-for-lykos-mdma-from-dr-marion-coe/ 2024-06-04T16:10:39+00:00 https://www.pinneyassociates.com/comment-on-nda-for-lykos-mdma-from-dr-jack-henningfield/ 2024-06-04T16:11:14+00:00 https://www.pinneyassociates.com/assessment-of-abuse-liability-and-switching-potential-of-menthol-flavored-pod-based-electronic-nicotine-delivery-systems-among-us-adults-who-smoke-cigarettes/ 2024-05-21T18:40:16+00:00 https://www.pinneyassociates.com/methods-used-by-us-adults-to-stop-smoking-cigarettes-2020-2022/ 2024-05-21T15:02:27+00:00 https://www.pinneyassociates.com/rising-uptake-of-alternative-nicotine-products-anps-by-smoking-naive-individuals-is-not-necessarily-a-threat-to-public-health-the-case-of-diversion-by-snus-in-norway/ 2024-05-21T14:58:16+00:00 https://www.pinneyassociates.com/popular-science-names-the-over-the-counter-switch-of-opill-as-one-of-the-50-greatest-innovations-of-2023/ 2023-12-22T16:22:34+00:00 https://www.pinneyassociates.com/nonclinical-studies-of-abuse-potential-with-dual-orexin-receptor-antagonists-concordance-with-real-world-use/ 2023-11-15T18:21:00+00:00 https://www.pinneyassociates.com/no-indication-of-abuse-or-withdrawal-potential-with-esmethadone-rel-1017-results-from-two-phase-3-randomized-placebo-controlled-trials-in-patients-with-major-depressive-disorder/ 2024-05-21T18:39:48+00:00 https://www.pinneyassociates.com/62nd-annual-meeting-of-the-american-college-of-neuropsychopharmacology-acnp/ 2023-11-15T18:26:53+00:00 https://www.pinneyassociates.com/17th-annual-pain-therapeutics-summit/ 2023-10-11T19:55:31+00:00 https://www.pinneyassociates.com/overview-of-the-current-regulatory-landscape-and-challenges-in-the-development-of-new-safer-and-effective-analgesic-drugs/ 2023-10-11T19:45:18+00:00 https://www.pinneyassociates.com/2023-chpas-regulatory-scientific-quality-conference-rsq/ 2023-08-31T14:19:59+00:00 https://www.pinneyassociates.com/2023-annual-srnt-e-conference/ 2023-08-29T16:24:04+00:00 https://www.pinneyassociates.com/what-will-it-take-to-move-the-harm-reduction-debate-forward/ 2023-10-11T19:36:40+00:00 https://www.pinneyassociates.com/counterfactual-trend-modeling-to-examine-how-youth-smoking-trends-changed-during-the-e-cigarette-era/ 2023-10-11T19:36:22+00:00 https://www.pinneyassociates.com/what-substances-are-adolescents-vaping-estimating-nicotine-specific-and-marijuana-specific-vaping-from-us-national-surveys/ 2023-10-11T19:37:51+00:00 https://www.pinneyassociates.com/updated-population-level-counterfactual-trend-modelling-to-examine-the-relationship-between-smoking-prevalence-and-e-cigarette-use-among-us-adults-and-adolescents/ 2023-10-11T19:38:21+00:00 https://www.pinneyassociates.com/2023-american-college-of-clinical-pharmacology-annual-meeting/ 2023-08-02T17:25:19+00:00 https://www.pinneyassociates.com/ccalcs-advancements-and-challenges-in-abuse-potential-evaluation-2023/ 2023-08-09T14:53:47+00:00 https://www.pinneyassociates.com/pinney-associates-inc-announces-leadership-team-promotions/ 2023-05-16T14:10:25+00:00 https://www.pinneyassociates.com/apa-2023/ 2023-06-26T20:48:49+00:00 https://www.pinneyassociates.com/within-subject-comparison-of-inter-individual-variations-in-opioid-induced-effects/ 2023-03-23T16:35:07+00:00 https://www.pinneyassociates.com/within-subject-variations-in-opioid-sensitivity-across-patient-reported-outcomes-observer-ratings-physiological-endpoints-and-analgesic-responses/ 2023-03-23T16:08:20+00:00 https://www.pinneyassociates.com/maps-psychedelic-science-2023/ 2023-06-07T16:36:40+00:00 https://www.pinneyassociates.com/abuse-potential-similarities-between-hypnotic-classes-real-world-data/ 2023-03-16T19:31:15+00:00 https://www.pinneyassociates.com/cpdd-85th-annual-scientific-meeting/ 2023-03-23T16:11:59+00:00 https://www.pinneyassociates.com/a-novel-3-mg-naloxone-nasal-spray-for-the-over-the-counter-market/ 2023-03-16T16:57:53+00:00 https://www.pinneyassociates.com/differing-approaches-to-investigating-the-therapeutic-efficacy-of-psilocybin-across-diverse-indications/ 2023-03-16T16:37:51+00:00 https://www.pinneyassociates.com/abuse-potential-differs-between-hypnotic-classes-real-world-data/ 2023-03-16T18:30:19+00:00 https://www.pinneyassociates.com/cure-addiction-now-forum-webinar/ 2023-03-16T15:47:15+00:00 https://www.pinneyassociates.com/2023-chpa-annual-self-care-leadership-summit/ 2023-02-09T20:22:35+00:00 https://www.pinneyassociates.com/coresta-crom-symposium-2023/ 2023-02-09T20:22:57+00:00 https://www.pinneyassociates.com/policy-considerations-that-support-equitable-access-to-responsible-accountable-safe-and-ethical-uses-of-psychedelic-medicines/ 2023-02-09T20:23:29+00:00 https://www.pinneyassociates.com/psychedelic-assisted-psychotherapy-to-treat-psychiatric-and-existential-distress-in-life-threatening-medical-illnesses-and-palliative-care/ 2023-02-09T20:23:49+00:00 https://www.pinneyassociates.com/psychedelic-drug-abuse-potential-assessment-for-new-drug-applications-and-controlled-substance-scheduling-a-united-states-perspective/ 2023-02-09T20:24:08+00:00 https://www.pinneyassociates.com/6th-annual-summit-on-controlled-substances-regulation-litigation-and-enforcement/ 2023-02-09T20:24:25+00:00 https://www.pinneyassociates.com/respiratory-effects-of-oral-mitragynine-and-oxycodone-in-a-rodent-model/ 2023-02-09T20:25:15+00:00 https://www.pinneyassociates.com/16th-annual-pain-therapeutics-summit/ 2023-02-09T20:25:31+00:00 https://www.pinneyassociates.com/wonderland/ 2023-02-09T20:26:05+00:00 https://www.pinneyassociates.com/interdisciplinary-conference-on-psychedelic-research-icpr-2022/ 2023-02-09T20:26:24+00:00 https://www.pinneyassociates.com/2022-cannabis-science-conference-east/ 2023-02-09T20:26:50+00:00 https://www.pinneyassociates.com/2022-public-health-law-summit/ 2023-02-09T20:27:25+00:00 https://www.pinneyassociates.com/painweek-conference-2022/ 2023-02-09T20:27:47+00:00 https://www.pinneyassociates.com/team/megan-harris/ 2026-03-12T16:13:37+00:00 https://www.pinneyassociates.com/adherence-among-a-cohort-taking-progestin-only-pills-prescribed-by-a-healthcare-provider-results-of-the-benchmark-study/ 2023-02-09T20:28:09+00:00 https://www.pinneyassociates.com/2nd-rems-innovation-summit/ 2023-02-09T20:28:31+00:00 https://www.pinneyassociates.com/aspen-ideas-health-2/ 2023-02-09T20:28:55+00:00 https://www.pinneyassociates.com/from-bench-to-bedside-to-policy-updating-our-understanding-of-kratom/ 2023-02-09T20:29:15+00:00 https://www.pinneyassociates.com/rel-1017-esmethadone-d-methadone-a-rapid-acting-antidepressant-has-no-meaningful-opioid-abuse-liability-in-nonclinical-and-clinical-abuse-potential-studies/ 2023-02-09T20:29:55+00:00 https://www.pinneyassociates.com/cpdd-84th-annual-scientific-meeting/ 2023-02-09T20:30:12+00:00 https://www.pinneyassociates.com/comment-to-proposed-2022-cdc-clinical-practice-guideline-for-prescribing-opioids-docket-no-cdc-2022-0024/ 2023-02-09T20:30:34+00:00 https://www.pinneyassociates.com/comment-to-the-fda-world-health-organization-ecdd-report-addressing-the-review-status-of-kratom-and-its-alkaloids-docket-no-fda-2022-n-0105/ 2023-02-09T20:30:58+00:00 https://www.pinneyassociates.com/chpa-annual-self-care-leadership-conference/ 2023-02-09T20:31:18+00:00 https://www.pinneyassociates.com/the-psychedelic-therapeutics-and-drug-development-conference/ 2023-02-09T20:31:41+00:00 https://www.pinneyassociates.com/team/lisa-zapawa/ 2022-11-30T23:17:12+00:00 https://www.pinneyassociates.com/team/daniel-wang/ 2022-02-10T20:25:45+00:00 https://www.pinneyassociates.com/team/christine-sweeney/ 2022-02-22T23:19:33+00:00 https://www.pinneyassociates.com/team/bernie-simone/ 2024-03-01T20:12:36+00:00 https://www.pinneyassociates.com/team/saul-shiffman/ 2025-06-06T15:41:54+00:00 https://www.pinneyassociates.com/team/mark-sembower/ 2022-03-31T14:32:45+00:00 https://www.pinneyassociates.com/team/arielle-selya/ 2024-11-01T12:20:19+00:00 https://www.pinneyassociates.com/team/sarah-scholl/ 2022-04-28T16:23:31+00:00 https://www.pinneyassociates.com/team/steve-pype/ 2022-02-17T00:21:25+00:00 https://www.pinneyassociates.com/team/ryan-lanier/ 2025-10-27T20:40:00+00:00 https://www.pinneyassociates.com/team/sooyong-kim/ 2022-02-22T23:20:53+00:00 https://www.pinneyassociates.com/team/marilyn-huestis/ 2025-07-24T18:56:02+00:00 https://www.pinneyassociates.com/team/jack-henningfield/ 2022-03-01T20:06:44+00:00 https://www.pinneyassociates.com/team/michael-hannon/ 2022-02-17T00:21:13+00:00 https://www.pinneyassociates.com/team/caitlyn-durgin/ 2023-07-26T15:45:00+00:00 https://www.pinneyassociates.com/team/floe-foxon/ 2026-01-22T13:36:34+00:00 https://www.pinneyassociates.com/team/michelle-ertischek/ 2022-02-17T00:19:21+00:00 https://www.pinneyassociates.com/team/marion-coe/ 2025-05-12T18:52:53+00:00 https://www.pinneyassociates.com/team/steve-choi/ 2022-02-22T23:20:25+00:00 https://www.pinneyassociates.com/team/judy-ashworth/ 2025-02-25T15:56:06+00:00 https://www.pinneyassociates.com/team/lucy-owen/ 2025-02-26T14:31:07+00:00 https://www.pinneyassociates.com/team/joe-gitchell/ 2024-11-18T18:41:18+00:00 https://www.pinneyassociates.com/team/john-pinney/ 2025-06-06T15:41:44+00:00 https://www.pinneyassociates.com/psychedelic-drugs-in-the-post-approval-world-important-components-of-risk-evaluation-and-mitigations-strategy-rems-programs-to-protect-public-health-while-ensuring-widespread-access/ 2023-02-10T14:54:55+00:00 https://www.pinneyassociates.com/no-meaningful-opioid-abuse-liability-of-rel-1017-esmethadone-d-methadone-a-rapid-acting-antidepressant-in-clinical-development-a-human-abuse-potential-study/ 2023-02-10T14:55:18+00:00 https://www.pinneyassociates.com/comparison-between-the-2020-cpdd-membership-survey-and-meeting-attendance-transition-from-meeting-attendance-to-membership/ 2023-02-10T14:55:40+00:00 https://www.pinneyassociates.com/making-mdma-a-medicine-analysis-of-the-8-factors-of-the-controlled-substances-act-for-the-abuse-potential-of-mdma/ 2023-02-10T14:56:02+00:00 https://www.pinneyassociates.com/the-15th-annual-pain-therapeutics-summit/ 2023-02-10T14:56:42+00:00 https://www.pinneyassociates.com/4th-annual-neuropsychiatric-drug-development-summit/ 2023-02-10T14:57:29+00:00 https://www.pinneyassociates.com/considerations-for-the-future-of-rx-to-otc-switches/ 2023-02-10T14:59:28+00:00 https://www.pinneyassociates.com/rel-1017-esmethadone-showed-no-reinforcing-properties-compared-to-oxycodone-in-rat-self-administration-study/ 2023-02-10T14:59:52+00:00 https://www.pinneyassociates.com/meeting-the-challenge-of-the-psychedelics-and-cns-drugs-with-novel-mechanisms-building-on-the-foundation-of-the-fda-2017-guidance-on-the-assessment-of-abuse-potential/ 2023-02-10T15:00:19+00:00 https://www.pinneyassociates.com/rel-1017-esmethadone-demonstrates-no-withdrawal-effects-or-evidence-of-physical-dependence-in-a-rat-study/ 2023-02-10T15:01:19+00:00 https://www.pinneyassociates.com/the-2020-cpdd-membership-survey-a-new-approach-to-assessing-diversity-and-inclusion-in-scientific-organizations/ 2023-02-10T15:02:02+00:00 https://www.pinneyassociates.com/results-of-the-2020-cpdd-membership-survey-we-are-more-diverse-than-suggested-by-earlier-survey-approaches/ 2023-02-10T15:02:38+00:00 https://www.pinneyassociates.com/abuse-potential-related-science-and-regulatory-perspectives-for-psychedelic-drug-product-development/ 2023-02-10T15:03:17+00:00 https://www.pinneyassociates.com/design-and-operational-challenges-in-psychedelic-clinical-trials/ 2023-02-10T15:03:40+00:00 https://www.pinneyassociates.com/complexities-of-planning-developing-and-validating-a-switch-opportunity-via-a-regulatory-pathway/ 2023-02-10T15:04:03+00:00 https://www.pinneyassociates.com/social-media-monitoring-versus-a-consumer-survey-to-elucidate-reasons-and-patterns-of-intake-among-kratom-users/ 2023-02-10T15:04:40+00:00 https://www.pinneyassociates.com/current-and-future-potential-impact-of-covid-19-on-kratom-mitragyna-speciosa-korth-supply-and-use/ 2023-02-10T15:04:59+00:00 https://www.pinneyassociates.com/targeting-differences-strategies-to-demonstrate-the-benefits-of-novel-cns-active-analgesics/ 2023-02-10T15:05:32+00:00 https://www.pinneyassociates.com/comment-to-the-fda-standards-for-future-opioid-analgesic-approvals-and-incentives-for-new-therapeutics-to-treat-pain-and-addiction/ 2023-02-10T15:06:13+00:00 https://www.pinneyassociates.com/the-nexus-of-opioids-pain-and-addiction-challenges-and-solutions/ 2023-02-10T15:06:37+00:00 https://www.pinneyassociates.com/kratom-policy-the-challenge-of-balancing-therapeutic-potential-with-public-safety/ 2023-02-10T15:07:20+00:00 https://www.pinneyassociates.com/a-reply-to-cdc-report-on-unintentional-drug-overdose-deaths-with-kratom-detected-2019-appropriate-regulation-of-kratom-and-improved-postmortem-testing-protocols-are-needed-immediately/ 2023-02-10T15:07:47+00:00 https://www.pinneyassociates.com/analysis-of-fdas-october-17-2017-basis-for-the-recommendations-to-control-mitragynine-and-7-hydroxymitragynine-in-schedule-i-of-the-controlled-substances-act/ 2023-02-10T15:08:09+00:00 https://www.pinneyassociates.com/kratom-science-letter-to-us-congressional-leadership-on-kratom-science-and-policy/ 2023-02-10T15:08:49+00:00 https://www.pinneyassociates.com/the-abuse-potential-of-medical-psilocybin-according-to-the-8-factors-of-the-controlled-substances-act/ 2023-02-10T15:09:30+00:00 https://www.pinneyassociates.com/rx-to-otc-switch-part-2-of-2-planning-for-commercial-success/ 2023-02-10T15:09:52+00:00 https://www.pinneyassociates.com/psychedelics-where-we-are-now-why-we-got-here-what-we-must-do/ 2023-02-10T15:10:20+00:00 https://www.pinneyassociates.com/rx-to-otc-switch-part-1-of-2-planning-for-regulatory-success/ 2023-02-10T15:11:13+00:00 https://www.pinneyassociates.com/kratom-science-letter-to-the-white-house-office-of-national-drug-control-policy/ 2024-06-04T16:15:31+00:00 https://www.pinneyassociates.com/exceeding-the-maximum-daily-dose-of-acetaminophen-with-use-of-different-single-ingredient-otc-formulations/ 2023-02-10T15:11:35+00:00 https://www.pinneyassociates.com/the-abuse-potential-of-kratom-according-to-the-8-factors-of-the-controlled-substances-act-implications-for-regulation-and-research/ 2023-02-10T15:11:56+00:00 https://www.pinneyassociates.com/a-cost-effectiveness-analysis-of-over-the-counter-statins/ 2023-02-10T15:12:39+00:00 https://www.pinneyassociates.com/ten-years-after-the-rx-to-otc-switch-of-nicotine-replacement-therapy-what-have-we-learned-about-the-benefits-and-risks-of-non-prescription-availability/ 2023-02-10T15:13:09+00:00 https://www.pinneyassociates.com/physician-involvement-in-recommending-over-the-counter-nicotine-replacement-therapy-research-letter/ 2023-02-10T15:13:35+00:00 https://www.pinneyassociates.com/chewing-gums-lozenges-candies-tablets-liquids-and-sprays-for-the-efficient-delivery-of-medications-and-dietary-supplements/ 2023-02-10T15:14:12+00:00